Corteva, Inc. (CTVA) Cash Flow Statement

The negative OCF/NI ratio in 2026Q2, despite a $1.2B net income, is primarily driven by a $1.4B working capital outflow, typical for the pre-harvest season. This pattern is consistent with prior years, where Q1 and Q2 show cash outflows while Q4 captures the bulk of collections. Investors should focus on the full-year cumulative conversion rather than quarterly swings, as the seasonal working capital cycle is a structural feature of the agricultural inputs business.

Excluding the Q4 seasonal surge, FCF in other quarters is thin or negative, with 2026Q2 showing -$588M. The average FCF margin over the last four quarters is roughly 12%, which is respectable but not exceptional for a company with CTVA's asset base. The modest revenue growth of 2.9% YoY and the softening commodity price environment may limit FCF expansion in the near term, warranting close monitoring of H2 2026 cash generation.

CapEx of $122M in 2026Q2 is modest relative to the $6.4B revenue, and the trend has been stable across quarters. This suggests that maintenance capex is well covered by operating cash flow, and the company has ample flexibility to allocate capital to dividends, buybacks, and acquisitions. The low capital intensity also supports the view that CTVA's cash flow quality is high, as depreciation ($339M in 2026Q2) is not a major drag on cash generation.

The large working capital outflows in Q1 and Q2 reflect the build-up of inventory and receivables ahead of the spring planting season, while Q4 captures the collection of those receivables. This is a structural feature of the agricultural inputs industry, but it means that quarterly cash flow figures are not indicative of annual performance. Investors should assess CTVA's cash generation on a trailing twelve-month basis to smooth out these seasonal distortions.

Dividends of $120M and buybacks of $250M in 2026Q2 are in line with prior quarters, indicating a stable capital return program. The company's low debt and $4.5B cash balance provide ample liquidity to fund these distributions even during seasonal cash troughs. However, the recent acquisitions in the biologicals space (Stoller and Symborg) may signal a shift toward M&A-led growth, which could compete with buybacks for capital in the future.

The gap between net income and operating cash flow is largely attributable to working capital swings, but the magnitude is notable. While the seasonal pattern explains some of the divergence, the cumulative shortfall implies that CTVA may be recognizing revenue before cash is collected, or that other non-cash items are inflating earnings. Investors should monitor the sustainability of this trend, as a persistent gap could signal aggressive revenue recognition or deteriorating receivables quality.